Zhuming Zhang

发表

Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.

Jing Zhang, Zhuming Zhang, Frank Podlaski, 2013, Journal of medicinal chemistry.

Counterion Pairing Effects on a Flavylium Heptamethine Dye †

E. Sletten, Zhuming Zhang, Monica Pengshung, 2021, Photochemistry and photobiology.

Assessing IRAK4 Functions in ABC DLBCL by IRAK4 Kinase Inhibition and Protein Degradation.

J. Edwards, U. Philippar, R. Attar, 2020, Cell chemical biology.

Diversity-Oriented Chemoenzymatic Synthesis of Sulfated and Nonsulfated Core 2 O-GalNAc Glycans.

Tiehai Li, Zhuming Zhang, Liuqing Wen, 2021, The Journal of organic chemistry.

Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis.

Yi Chen, K. Luk, A. Railkar, 2006, Bioorganic & medicinal chemistry letters.

Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer

Yolanda T. Chong, T. Bush, G. Bignan, 2021, Molecular Cancer Therapeutics.

Title: Discovery of JNJ-63576253, a next-generation androgen receptor antagonist active against wild- type and clinically-relevant ligand binding domain mutations in metastatic castration-resistant prostate cancer (mCRPC) Running Title: Discovery of JNJ-63576253, a next-generation AR antagonist

Yolanda T. Chong, T. Bush, G. Bignan, 2021 .

Selective protection of the C(7) and C(10) hydroxyl groups in 10-deacetyl baccatin III

Zhuming Zhang, D. Procter, P. Clarke, 1998 .

Stereoselective Synthesis of β-C-Glycosides of 3-Deoxy-d-manno-oct-2-ulosonic Acid (Kdo) via SmI2-Mediated Reformatsky Reactions.

Tiehai Li, Zhuming Zhang, Xingbang Liu, 2021, Organic letters.

Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy.

L. Vassilev, B. Graves, Z. Filipovic, 2014, Bioorganic & medicinal chemistry.

Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer.

Shefali R Patel, K. Bachman, V. Pande, 2021, Journal of medicinal chemistry.

AKR1C3 mediates pan‐AR antagonist resistance in castration‐resistant prostate cancer

C. Janetopoulos, G. Bignan, P. Connolly, 2020, The Prostate.

Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).

Yolanda T. Chong, T. Bush, G. Bignan, 2021, Journal of medicinal chemistry.

Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development.

S. So, L. Vassilev, B. Graves, 2014, ACS medicinal chemistry letters.

Potent Phenylpyridine and Oxodihydrofuran Inhibitors of Cyclooxygenase-2: Optimization toward a Long Residence Time with Balanced Internal Energetics.

P. Connolly, Zhuming Zhang, Kay Ahn, 2021, Biochemistry.

Abstract 1256: JNJ-74856665, a novel DHODH inhibitor, mediates potent anti-leukemic activity and differentiationin vitroandin vivo

E. Jacoby, T. Bush, S. Kuduk, 2021, Experimental and Molecular Therapeutics.

Discovery of a highly potent, orally active mitosis/angiogenesis inhibitor r1530 for the treatment of solid tumors.

K. Luk, P. Wovkulich, C. Tovar, 2013, ACS medicinal chemistry letters.

Preclinical evaluation of the novel multi-targeted agent R1530

D. Carvajal, A. Railkar, P. Wovkulich, 2011, Cancer Chemotherapy and Pharmacology.